Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI
- Analysis of 2 Cases.
10.3779/j.issn.1009-3419.2019.01.10
- VernacularTitle:EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析
- Author:
Meirong LIU
1
;
Fanlu MENG
1
;
Qing MA
1
;
Liyan GU
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Case Reports
- Keywords:
EGFR-TKI;
Lung neoplasms;
Primary resistance
- MeSH:
Carcinoma, Non-Small-Cell Lung;
diagnostic imaging;
drug therapy;
genetics;
Disease Progression;
Drug Resistance, Neoplasm;
drug effects;
genetics;
ErbB Receptors;
antagonists & inhibitors;
genetics;
Fatal Outcome;
Humans;
Lung Neoplasms;
diagnostic imaging;
drug therapy;
genetics;
Male;
Middle Aged;
Mutation;
Protein Kinase Inhibitors;
therapeutic use;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2019;22(1):52-56
- CountryChina
- Language:Chinese
-
Abstract:
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutations have primary drug resistance. It may be related to the coexistence of susceptible and resistant mutations of EGFR gene, downstream mutations of EGFR pathway, MET amplification and BIM deletion polymorphism. We present 2 cases of primary drug resistance and analyze the reasons.
.
